Evidence map›Paper›PMID 34268660›Full record

ArticleDigestive diseases and sciences2022

Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.

Baldeep S Pabla, C Alex Wiles, James C Slaughter, Elizabeth A Scoville, Robin L Dalal, Dawn B Beaulieu, David A Schwartz, Sara N Horst

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.Journal of the Canadian Association of Gastroenterology · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Baldeep S PablaDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA. baldeep.pabla@vumc.org.ORCID 0000-0003-4903-604X
C Alex WilesDepartment of Internal Medicine, Vanderbilt University Medical Center, Nashville, USA.
James C SlaughterDepartment of Biostatistics, Vanderbilt University, Nashville, USA.
Elizabeth A ScovilleDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA.
Robin L DalalDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA.
Dawn B BeaulieuDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA.
David A SchwartzDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA.
Sara N HorstDivision of Internal Medicine, Department of Gastroenterology, Vanderbilt Inflammatory Bowel Diseases Center, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20500, Nashville, TN, 37204, USA.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVedolizumab is a monoclonal antibody used to treat inflammatory bowel disease (IBD). There is little known about the safety and comparative efficacy of this agent in the elderly population.

aimsHere, we present data on the safety and comparative efficacy of vedolizumab versus tumor necrosis factor α antagonists (anti-TNF) in elderly patients with IBD.

methodsThis retrospective cohort study included IBD patients started on vedolizumab or anti-TNF at age 60 or older at a single tertiary IBD center. Safety was evaluated by assessing for the development of serious infection. The comparative needs for IBD-related surgery, IBD-related hospitalization, and drug discontinuation for any reason were obtained. Efficacy was assessed by comparing changes in endoscopic, histologic, and patient-report outcomes.

results212 cases were identified-108 patients treated with vedolizumab and 104 patients treated with anti-TNF. There were no significant differences between cohorts in serious infection, surgical intervention, or IBD-hospitalization-free survival (p = NS). Drug discontinuation survival was different between anti-TNF and vedolizumab (p = 0.02) with more patients remaining on vedolizumab at the time of last follow-up (51.9% vs. 25.9%). Endoscopic remission and response rates were higher in the vedolizumab versus anti-TNF group (65.7% vs. 45.2%, p = 0.02; 80.0% vs. 59.3%, p < 0.001).

conclusionsIn a cohort of IBD patients over age 60, vedolizumab showed no statistically significant differences in infection, hospitalization, or surgical intervention-free survival as compared to anti-TNF. Vedolizumab was discontinued less frequently than anti-TNF. Patients on vedolizumab had higher rates of endoscopic remission and response.

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesAgedAntibodies, Monoclonal, HumanizedGastrointestinal AgentsHumansMiddle AgedRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAntibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsvedolizumabAnti-TNFComparative effectivenessElderlySafetyVedolizumab

Identifiers

PMID34268660
OpenAlexW3181489183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.